Equities research analysts predict that Stryker Co. (NYSE:SYK) will announce earnings of $1.93 per share for the current fiscal quarter, according to Zacks. Eleven analysts have issued estimates for Stryker’s earnings, with the highest EPS estimate coming in at $1.96 and the lowest estimate coming in at $1.90. Stryker posted earnings per share of $1.76 during the same quarter last year, which would indicate a positive year over year growth rate of 9.7%. The business is expected to report its next quarterly earnings report on Tuesday, July 23rd.

According to Zacks, analysts expect that Stryker will report full year earnings of $8.15 per share for the current fiscal year, with EPS estimates ranging from $8.13 to $8.20. For the next financial year, analysts expect that the company will report earnings of $8.95 per share, with EPS estimates ranging from $8.85 to $9.06. Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that that provide coverage for Stryker.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, April 23rd. The medical technology company reported $1.88 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.84 by $0.04. Stryker had a net margin of 25.38% and a return on equity of 26.72%. The firm had revenue of $3.52 billion during the quarter, compared to analysts’ expectations of $3.51 billion. During the same period in the prior year, the company earned $1.68 EPS. The business’s quarterly revenue was up 8.5% compared to the same quarter last year.

SYK has been the topic of several recent analyst reports. Wells Fargo & Co raised their price target on Stryker from $214.00 to $219.00 and gave the company an “outperform” rating in a report on Monday, April 1st. Zacks Investment Research lowered Stryker from a “buy” rating to a “hold” rating in a research report on Friday, April 12th. BTIG Research raised their target price on Stryker to $211.00 and gave the company a “buy” rating in a research note on Monday, March 18th. Barclays lifted their price objective on Stryker from $203.00 to $211.00 and gave the company an “overweight” rating in a research note on Monday, April 15th. Finally, JPMorgan Chase & Co. lifted their price objective on Stryker from $200.00 to $215.00 and gave the stock an “overweight” rating in a report on Tuesday, March 19th. Seven research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $196.89.

Stryker stock traded up $1.51 during trading on Wednesday, hitting $185.69. 35,906 shares of the company were exchanged, compared to its average volume of 1,484,821. Stryker has a 52 week low of $144.75 and a 52 week high of $199.85. The company has a current ratio of 2.12, a quick ratio of 1.30 and a debt-to-equity ratio of 0.68. The company has a market capitalization of $68.73 billion, a P/E ratio of 25.44, a price-to-earnings-growth ratio of 2.24 and a beta of 0.84.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 31st. Shareholders of record on Friday, June 28th will be paid a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 1.12%. The ex-dividend date of this dividend is Thursday, June 27th. Stryker’s dividend payout ratio is currently 28.45%.

In other news, VP Katherine Ann Owen sold 29,247 shares of the firm’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $185.62, for a total value of $5,428,828.14. Following the transaction, the vice president now owns 11,131 shares of the company’s stock, valued at approximately $2,066,136.22. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Glenn S. Boehnlein sold 2,700 shares of the firm’s stock in a transaction on Wednesday, May 8th. The shares were sold at an average price of $188.21, for a total transaction of $508,167.00. Following the completion of the transaction, the chief financial officer now directly owns 23,333 shares in the company, valued at approximately $4,391,503.93. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 111,550 shares of company stock worth $21,374,171. 7.20% of the stock is currently owned by insiders.

Several hedge funds have recently modified their holdings of SYK. Farmers National Bank acquired a new stake in Stryker during the 1st quarter valued at $25,000. Cable Hill Partners LLC acquired a new position in Stryker during the 1st quarter worth $30,000. RPG Investment Advisory LLC grew its holdings in Stryker by 160.0% during the 1st quarter. RPG Investment Advisory LLC now owns 156 shares of the medical technology company’s stock worth $31,000 after acquiring an additional 96 shares in the last quarter. ERTS Wealth Advisors LLC acquired a new position in Stryker during the 4th quarter worth $25,000. Finally, Northwest Wealth Management LLC grew its holdings in Stryker by 103.6% during the 4th quarter. Northwest Wealth Management LLC now owns 169 shares of the medical technology company’s stock worth $26,000 after acquiring an additional 86 shares in the last quarter. 74.71% of the stock is currently owned by institutional investors and hedge funds.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Recommended Story: Market Capitalization – What it Means for Investors

Get a free copy of the Zacks research report on Stryker (SYK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.